| Literature DB >> 15243116 |
T R Anderegg1, R N Jones, H S Sader.
Abstract
BAL9141 is a novel cephalosporin with a broad spectrum of activity, including activity against methicillin-resistant staphylococci. This multicenter study was performed to establish quality control (QC) guidelines for susceptibility testing of BAL9141 in phase 3 clinical trials and after U.S. Food and Drug Administration approval. The proposed 3 or 4 log(2) dilution MIC ranges encompass 97.8 to 100.0% of reported results, while the proposed 7- to 9-mm-zone-diameter QC ranges included 95.2 to 99.4% of the participant-reported disk diffusion results.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15243116 PMCID: PMC446259 DOI: 10.1128/JCM.42.7.3356-3358.2004
Source DB: PubMed Journal: J Clin Microbiol ISSN: 0095-1137 Impact factor: 5.948